Skip to main content
. 2023 Mar 22;31(5):434–439. doi: 10.1136/ejhpharm-2022-003403

Table 1.

Demographic background and clinical characteristics of enrolled patients for modelling

Characteristics Number or mean±SD Median (range)
No. Patients 51
No. Observations 196
Observations per patient 3.84
No. Male/Female 33/18
No. AKI 20 (39.21%)
No. Hepatic insufficiency 26 (50.98%)
No. Sepsis shock 18 (35.29%)
No. Ventilation 26 (50.98%)
No. Respiratory infection 27 (52.94%)
No. Bloodstream infection 2 (0.04%)
No. Other infection 22 (43.14%)
Course of treatment (d) 9.35±3.94 9 (3-19)
Dose (mg) 519.61±97.05 500 (500–1000)
Daily dose (mg) 2032.26±286.80 2000 (1500–3000)
Age (year) 56.45±18.76 56 (18–96)
Body weight (kg) 70.21±72.01 69 (19.6–311.7)
Cr (μmol/L) 94.35±187.94 64.8 (32.8–883)
CrCl (mL/min) 104.59±60.95 99.34 (17.80–256.22)
APACHE II score 16.67±6.44 15 (8–33)
SOFA 6.78±5.06 5 (2-19)

Hepatic insufficiency: Child-Pugh B&C.

Sepsis shock: Compliance with diagnostic criteria of sepsis 3.0.

By measuring the serum creatinine level, the Cockcroft formula was used to calculate the endogenous creatinine clearance (CrCl), CrCl = [(140-age) × weight (kg)] / [0.818×Cr (μmol / L)]. For women, the calculation result × 0.85.

AKI, Acute Kidney Injury, Compliance with Kidney Disease: Improving Global Outcomes (KDIGO) AKI Guideline 2021; APACHE, Acute Physiology and Chronic Health Evaluation; Cr, Serum Creatinine; CrCl, Serum Creatinine Clearance; SOFA, Sequential Organ Failure Assessment.